RootK KRX:195990KOSDAQ
에이비프로바이오 · Korean news coverage and regulatory filings, organized.
In Q3 2026, RootK reported revenue of ₩10.3bn, up 30.8% year on year, and an operating loss of ₩1.8bn. RootK (에이비프로바이오) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals 4 quarters of losses Screener
RootK today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates RootK stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
RootK quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩10.3bn | +30.8% | −₩1.8bn margin −17.4% | −₩3.2bn |
| Q2 2026 | ₩9.0bn | -1.1% | −₩4.1bn margin −45.6% | −₩5.8bn |
| Q1 2026 | ₩7.9bn | -11.1% | −₩2.3bn margin −28.7% | ₩2.1bn |
| Q4 2025 derived | ₩6.1bn | -41.3% | −₩1.8bn margin −29.6% | −₩1.1bn |
| Q3 2025 | ₩7.9bn | -40.7% | −₩1.7bn margin −21.6% | −₩206m |
| Q2 2025 | ₩9.1bn | +365.6% | −₩2.5bn margin −27.7% | −₩44.4bn |
| Q1 2025 | ₩8.9bn | +45.3% | −₩3.3bn margin −36.8% | −₩3.3bn |
| Q4 2024 derived | ₩10.3bn | +69.9% | −₩3.5bn margin −34.0% | −₩22.2bn |
RootK ranks #1930 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
RootK top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.